Director, President and CEO · ENANTA PHARMACEUTICALS INC · Common Stock
Side
A
Value
—
Shares
15.2K
Price
—
Executed
Feb 12, 2026
Disclosed
Feb 13, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Feb 12 executedFeb 13, 2026 disclosed
ENTA · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 1.8% of prior position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Luly Jay R. filed this Form 4 reporting a grant or award of ENTA on Feb 12, 2026. It became public on Feb 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, President and CEO
Luly Jay R.cik:0001571211
Issuer
ENANTA PHARMACEUTICALS INCcik:0001177648
Revision history · 0
No field has changed since this record was first ingested.
